BP1 is a transcription factor that has earned growing attention in cancer biology for its frequent overexpression in breast tumors, leukemia, and lung cancer, among other malignancies. Formally classified as an isoform of the DLX4 homeobox gene, BP1 was first identified through its ability to repress the beta-globin gene, but research over the past two decades has uncovered a far broader set of functions and disease associations. Its story is one of a developmental regulator that, when switched on in the wrong cells at the wrong time, appears to promote tumor survival and spread.
A Homeobox Gene With Developmental Roots
BP1 belongs to the Distal-less (DLX) subfamily of homeobox genes, a family of transcription factors that play central roles in early embryonic development. Sequencing showed that BP1 shares its DNA-binding homeodomain and downstream sequences with another transcript called DLX7, differing only in the front portion of its messenger RNA. Both map to chromosome 17q21-22, confirming that they arise from the same gene through alternative splicing.1PubMed. Distinct functions of two isoforms of a homeobox gene, BP1 and DLX7, in the regulation of the beta-globin gene Despite sharing a homeodomain, BP1 and DLX7 do not behave identically: BP1 represses the beta-globin gene, while DLX7 activates it, a neat illustration of how alternative splicing can produce proteins with opposing effects from a single stretch of DNA.2PubMed Central. BP1, a homeodomain-containing isoform of DLX4, represses the beta-globin gene
Outside of blood-cell biology, DLX4 and its isoforms contribute to craniofacial development. In mouse embryos, the gene is active in the tissue that will become the palate, and variants in human DLX4 have been linked to orofacial clefting and abnormal jaw formation.3Human Molecular Genetics. DLX4 is associated with orofacial clefting and abnormal jaw development In normal adult bone marrow, BP1 expression is largely confined to more mature blood cell populations (CD34-negative cells) and is essentially absent in the immature stem-like cells marked by CD34.4PubMed. BP1, a new homeobox gene, is frequently expressed in acute leukemias That pattern makes its reappearance in leukemic blasts and solid tumors all the more striking.
How BP1 Promotes Tumor Growth at the Molecular Level
When researchers have looked at what BP1 actually does inside cancer cells, a consistent theme emerges: it tips the balance toward survival, growth, and invasiveness. One of its best-characterized actions is direct activation of BCL-2, a protein that blocks programmed cell death. In breast cancer cells engineered to overexpress BP1, the levels of BCL-2 messenger RNA and protein both rose. When those cells were challenged with the inflammatory signal TNFα, which normally triggers apoptosis, they resisted death far more effectively than control cells. BP1 overexpression shut down the cascade of enzymes (caspases) that normally dismantle a dying cell.5PubMed Central. BP1 transcriptionally activates bcl-2 and inhibits TNFα-induced cell death in MCF7 breast cancer cells
Beyond blocking cell death, BP1 activates genes involved in blood-vessel formation and cell proliferation. It has been shown to switch on VEGF, which promotes the growth of new blood vessels that tumors need to sustain themselves, and c-MYC, one of the most well-known cancer-driving genes.6Molecular Cancer Research. BP1 is an important biomarker in breast cancer A genome-wide screen in estrogen-receptor-negative breast cancer cells identified 18 direct BP1 target genes spanning a range of cancer-promoting pathways, from invasion to metastasis.7PubMed Central. Genome-wide analysis of BP1 transcriptional targets in breast cancer cell line Hs578T
Perhaps most consequential for aggressive disease, BP1 can push breast cancer cells through a process called epithelial-to-mesenchymal transition, where tumor cells lose their adhesion to neighboring cells and gain the ability to migrate and invade. BP1 does this by binding to the promoter region of the Twist gene, ramping up Twist protein along with the inflammatory cytokine IL-6. Cells overexpressing BP1 lost the adhesion molecule E-cadherin, gained mesenchymal markers like vimentin and fibronectin, and physically changed shape to become more spindle-like and migratory.8Cancer Research. BP1 induces an epithelial to mesenchymal transition in breast cancer cells by modulating the Twist/IL6 pathway
BP1 Expression in Breast Cancer
The clinical data on BP1 in breast cancer are among the most developed. In a study of 46 invasive ductal breast tumors, about 80% expressed BP1, compared with negligible expression in normal breast tissue.9PubMed Central. Correlation of expression of BP1, a homeobox gene, with estrogen receptor status in breast cancer That number alone is noteworthy, but the pattern within the data tells a sharper story. Every single estrogen-receptor-negative tumor in the study was BP1-positive, while about 73% of estrogen-receptor-positive tumors expressed BP1. The association with estrogen-receptor negativity matters because those tumors do not respond to standard hormone-blocking drugs like tamoxifen.10PubMed. BP1, a potential biomarker for breast cancer prognosis
The same study also turned up a disparity by race: roughly 89% of tumors from African American women were BP1-positive versus 57% from Caucasian women. That gap was statistically significant, though its biological explanation remains unclear.9PubMed Central. Correlation of expression of BP1, a homeobox gene, with estrogen receptor status in breast cancer Whether BP1 contributes mechanistically to racial disparities in breast cancer outcomes or simply correlates with other molecular features that differ between populations is an open question researchers have flagged but not resolved.
Immunostaining work paints a picture of BP1 expression rising in lockstep with disease progression. In tissue samples that included a spectrum of benign and malignant lesions, BP1 staining was barely detectable in normal breast tissue, present in about 21% of hyperplastic (overgrown but not yet cancerous) tissue, roughly 46% of in-situ carcinomas, and 81% of infiltrating cancers. When a single patient’s sample contained tissue at multiple stages, the most invasive areas consistently showed the most intense BP1 staining.11PubMed. Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion
Tamoxifen Resistance and Estrogen Independence
One of the more clinically worrying findings involves BP1 and drug resistance. Breast cancer cells engineered to overexpress BP1 showed increased expression of BCAR1, a gene associated with anti-estrogen resistance. When treated with tamoxifen, these BP1-overexpressing cells actually proliferated faster, while control cells showed the expected growth suppression.12PubMed Central. Beta protein 1 homeoprotein induces cell growth and estrogen-independent tumorigenesis by binding to the estrogen receptor in breast cancer This raises the possibility that high BP1 expression could serve as a warning flag for tumors likely to resist standard hormonal therapy, though clinical validation in large patient cohorts is still needed.
The connection between BP1 and BCL-2 adds another layer to the resistance picture. High BCL-2 levels have long been linked to resistance to both chemotherapy and radiation. If BP1 is driving BCL-2 up in a subset of tumors, those tumors could be harder to treat by multiple approaches, not just endocrine therapy.6Molecular Cancer Research. BP1 is an important biomarker in breast cancer
BP1 in Acute Myeloid Leukemia
BP1’s clinical links extend well beyond the breast. In acute myeloid leukemia (AML), the gene is overexpressed in roughly 63% of patients. The rate is particularly high in children, with about 81% of pediatric AML cases showing BP1 expression versus 47% of adult cases. In leukemia cell lines, forcing BP1 expression increased the cells’ ability to form colonies, consistent with a role in fueling leukemic growth.4PubMed. BP1, a new homeobox gene, is frequently expressed in acute leukemias
The prognostic picture in AML is grim for patients with high BP1 levels. In a study of de novo AML patients, those with elevated BP1 expression achieved complete remission at significantly lower rates and had shorter overall survival compared to patients with low BP1 expression. This held true across the full AML cohort, in the non-M3 subtype, and in patients with cytogenetically normal AML. Multivariate analysis confirmed BP1 as an independent risk factor, meaning its prognostic value was not simply a stand-in for other known risk markers.13PubMed. BP1 overexpression is associated with adverse prognosis in de novo acute myeloid leukemia
There is also evidence that BP1 interferes with a specific therapy for a particular AML subtype. In acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) is a cornerstone treatment. BP1 overexpression has been associated with resistance to ATRA in laboratory models, suggesting the gene may blunt the effectiveness of differentiation therapy in this otherwise highly treatable form of leukemia.14PubMed. Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells
BP1 in Lung Cancer
Lung cancer tissue shows a pattern of BP1 overexpression that mirrors what is seen in breast tumors and leukemia. In one study, BP1 was overexpressed in 36 lung cancer tissue samples and in adjacent tissues showing early changes, but was absent from normal lung tissue. Expression correlated with the tumor’s differentiation level but not with clinical stage, hinting that BP1 may be more relevant to a tumor’s biological character than to how far it has physically spread.15PubMed. Clinicopathological significance of homeobox BP1 mRNA expression in lung cancer tissue
From a prognostic standpoint, high BP1 messenger RNA levels in non-small cell lung cancer (NSCLC) patients predicted worse outcomes for both disease-free survival and overall survival. BP1 expression emerged as an independent prognostic factor for disease-free survival, suggesting it could eventually serve as a marker to identify NSCLC patients at higher risk of recurrence.16PubMed. Prognostic significance of BP1 mRNA expression level in patients with non-small cell lung cancer
An Unexpected Connection to Preeclampsia
Not all of BP1’s clinical associations involve cancer. DLX4 expression turned out to be reduced in placentas affected by preeclampsia, a dangerous pregnancy complication involving high blood pressure and organ damage. When researchers knocked down DLX4 in a trophoblast cell line (the cells that form the outer layer of the placenta and invade the uterine wall), the cells became less motile and less invasive. The molecular signature looked like a disruption of the epithelial-to-mesenchymal transition process, with E-cadherin dropping and its repressor Snail rising.17Reproductive Sciences. Regulation of epithelial-mesenchymal transition by homeobox gene DLX4 in JEG-3 trophoblast cells: a role in preeclampsia
This is an interesting inversion of what happens in cancer. In tumors, BP1/DLX4 overexpression drives EMT and promotes invasiveness. In the placenta, where trophoblast invasion is a normal and necessary process, loss of DLX4 appears to impair that invasion and contribute to disease. The same molecular program that makes cancer more dangerous is apparently essential for a healthy pregnancy. It underscores how context-dependent the effects of a single transcription factor can be.
Why BP1 Is Not Yet a Clinical Biomarker
Given the consistency of the data across multiple cancer types, a reasonable question is why BP1 has not already entered routine clinical use as a diagnostic or prognostic marker. Several obstacles stand in the way. Most of the studies to date have been relatively small, often involving a few dozen to a couple hundred patient samples. The breast cancer work, for example, drew its key finding of 80% expression from 46 tumors. These numbers are suggestive but fall short of the large, multi-site validation studies that regulatory agencies and clinical guideline panels require before endorsing a new biomarker.
Another challenge is specificity. BP1 is overexpressed in breast cancer, AML, and lung cancer, and its downstream effects on BCL-2 and EMT are common across many tumor types. A marker that lights up in multiple unrelated cancers is harder to build a targeted diagnostic test around than one specific to a single disease. It may ultimately prove more useful as a prognostic indicator within a given cancer type, helping clinicians assess how aggressive a particular tumor is likely to behave, rather than as a screening tool.
There is also the practical question of measurement. Much of the existing research used techniques like reverse-transcription PCR and immunohistochemistry on tissue samples, which are standard in research labs but require specific reagents and validated protocols before they can be rolled out across hospital pathology departments. Standardizing cutoff values for “high” versus “low” BP1 expression across different laboratory platforms is a non-trivial task that typically adds years to the path from research finding to clinical test.
Confusing Names in the Literature
Anyone searching the scientific literature for “BP1” will quickly encounter a naming headache. The homeobox transcription factor discussed throughout this article, formally DLX4 transcript variant 1, shares its abbreviation with an entirely unrelated protein: eukaryotic initiation factor 4E-binding protein 1, commonly written as 4E-BP1. That protein is a key node in the mTOR signaling pathway and has its own extensive cancer literature, particularly in prostate, ovarian, and bladder cancers. The two proteins have nothing in common structurally or functionally. 4E-BP1 regulates how cells translate messenger RNA into protein, while BP1 (DLX4) is a DNA-binding transcription factor that controls which genes are turned on or off.
The overlap in abbreviations causes genuine confusion in database searches. A PubMed query for “BP1 cancer” will return papers about both molecules interleaved in the results. Researchers in the field tend to distinguish them by using “DLX4” or “DLX4/BP1” for the homeobox gene and “4E-BP1” or “EIF4EBP1” for the translation-regulation protein. If you are reading the primary literature, checking which gene family a paper is discussing in its introduction will quickly resolve the ambiguity. But it is a real stumbling block for newcomers, and it is worth being aware of before you go digging into studies on your own.